to the contamination of BC with this organism [2] . That same year, an editorial entitled "Failure of Disinfectants to Disinfect" appeared in Lancet [3] , and reports of other outbreaks [4] [5] [6] prompted another editorial in 1970, entitled "Disinfectants That Don't" [1] . Additional outbreaks of infection occurred in the early 1970s [7] [8] [9] , resulting in a third editorial in 1976 [10] . At that time, a recommendation was made that BC be used only for environmental disinfection. Nevertheless, BC continued to be used as an antiseptic, and other outbreaks of infection occurred [11] [12] [13] [14] [15] [16] . As recently as 1991, a survey of members of the Society of Hospital Epidemiology of America revealed that 12% of hospitals still used BC as a skin disinfectant [17] .
On 23 July 1999, an infectious diseases physician reported 6 patients with Mycobacterium chelonae/Mycobacterium abscessus joint and soft-tissue infections to the Texas Department of Health (Austin). All patients had previously been seen at another private clinic and treated with intra-or periarticular steroids for arthralgia, arthritis, or calcaneal spurs by a physician during the preceding 4 months. This report describes the outbreak of and risk factors for infection.
PATIENTS, MATERIALS, AND METHODS

Case Definition
We defined a "presumptive case patient" as any person who sought medical care for an infected joint or surrounding tissue after receiving an intra-articular or periarticular steroid injection that had been administered by a single physician during the period of 1 April through 31 July 1999. We defined a "confirmed case patient" as any person from whom M. abscessus was cultured from either a joint fluid specimen or a periarticular soft-tissue specimen and who had received an intra-articular or periarticular injection by the physician during this time period.
Case Finding
The physician provided a list of all patients billed for intraarticular or periarticular injections during the period of 1 April through 31 July 1999 and contacted each of them. We asked the physician and the local infectious diseases physician to report any new cases. We reviewed the laboratory records from 2 local hospitals for 1997-1999 and solicited reports of cultures positive for M. chelonae or M. abscessus from other laboratories performing mycobacterial culturing in Texas.
Observational Visit
Before our visit, the physician had relocated to another office in a nearby building. In the previous office, the physician had administered intra-articular or periarticular steroid injections to the 6 case patients. The injection procedure consisted of cleaning the skin with cotton balls soaked in diluted BC (Zephiran; Sanofi Pharmaceuticals), painting the skin with commercially prepared iodine swabs, spraying the area with ethyl chloride and/or injecting 0.5 mL of 1% lidocaine HCl with a sterile 22-gauge needle and syringe, and injecting 0.5-1.0 mL of betamethasone phosphate into the joint with a sterile 20-gauge needle and syringe.
The commercial BC preparation (dilution, 1:750, or 0.13%) was first diluted with distilled water. Approximately 238 mL of commercial BC was mixed with 1.645 L of distilled water in a 1.9-L jug (dilution, ∼1:6000, or 0.017%). This stock solution was then poured over cotton balls into metallic containers or over -cm gauze pads into glass jars. The metal con-7.6 ϫ 7.6 tainers and glass jars had loose-fitting covers.
Obtaining Environmental Samples
The physician's current office contained 3 examination rooms. A swab of the inside surface of an open metal container that contained forceps was taken from room one. From each of the 3 rooms, the following were collected for culture: diluted BC-soaked cotton balls; a swab of the inside surface of a metallic container of cotton balls soaked in diluted BC; diluted BC-soaked, -cm gauze pads; and a swab of the inside 7.6 ϫ 7.6 surface of a glass jar that contained -cm gauze pads 7.6 ϫ 7.6 soaked in diluted BC.
Samples of ethyl chloride spray, lidocaine HCl, undiluted BC, iodine prep swabs, betamethasone phosphate, and diluted BC and a sealed bottle of locally purchased distilled water intended for diluting the BC were also obtained. A tap water sample was obtained from each of the 3 treatment rooms in the physician's previous office.
Laboratory Processing
We vortexed each swab sample in 3 mL of sterile phosphate buffer. Cotton balls and gauze pads were processed in 100 mL of buffer in a Seward Stomacher Model 400 (Seward Medical). A high-volume liquid sample (у100 mL) was concentrated on a 0.45-mm membrane filter that was then processed in 5 mL of buffer in the Seward Stomacher. For each sample, the buffer suspension was inoculated onto a set of media that consisted of a Mycobacterium Growth Indicator Tube (BACTEC MGIT 960; Becton Dickinson Microbiology Systems), a Lowenstein-Jensen agar slant, a Middlebrook 7H11 agar plate, and a Middlebrook 7H11 Selective Agar plate. Two sets of cultures were inoculated; one was incubated at 30ЊC, and the other was incubated at 35ЊC. The MGIT 960 medium was monitored continuously for growth using the MGIT 960 instrument, in accordance with the manufacturer's instructions (Becton Dickinson Microbiology Systems). Solid media were examined weekly for growth [18] . Except for the 7H11 plates, which were incubated for 3 weeks, all media were incubated for a total of 6 weeks before the medium was considered to be negative for acid-fast bacilli (AFB). A sample was reported to be contaminated when all culture media were overgrown by organisms other than AFB.
Organism Identification
Cultures were identified as belonging to the M. abscessus/ M. chelonae group on the basis of typical growth and colony morphology, occurrence of growth in р7 days, and presence of typical mycolic acids revealed by high-performance liquid chromatography (HPLC) with fluorescence detection of the cell wall mycolic acids [19] . Identification of M. abscessus was determined on the basis of a negative reaction by the citrate utilization test and a 5% sodium chloride-tolerance test result. Species identification was confirmed by PCR restriction analysis of a 439-bp sequence of the 65-hsp gene, as described elsewhere [20, 21] .
PFGE
Patterns of large restriction fragments of genomic DNA were obtained by PFGE, as described elsewhere [22] . Organisms recovered from liquid cultures were incorporated into low-meltingpoint agarose plugs, lysed by lysozyme (1 mg/mL), sodium dodecyl sulfate (1%), and proteinase K (1 mg/mL), then digested with the restriction endonucleases DraI and XbaI. Fragments were separated by PFGE using the CHEF Mapper System (BioRad Laboratories). Strains were considered to be the same or different on the basis of the criteria of Tenover et al. [23] . Twelve random strains of M. abscessus were chosen as controls for both PFGE and random amplified polymorphic DNA PCR (RAPD-PCR). These strains were recovered from sporadic clinical specimens that had previously been obtained from diverse Texas and Florida locations during the period of 1995-1997.
RAPD-PCR
RAPD-PCR was performed as described elsewhere [24, 25] , with modification. Both purified DNA extracted by phenol and crude ground cell supernatant obtained with a bead beater [21] were used as template DNA for PCR amplification. RAPD-PCR patterns for each of the template DNA extraction methods were compared. Four random primers (OPA2 [5 -TGCCGAG-CTG-3 ] and OPA18 [5 -AGGTGACCGT-3 ], described by Kauppinen et al. [26] , and INS-2 [5 -GCGTAGGCGTCGGTGAC-AAA-3 ] and IS986-FP [5 -ACGCTCAACGCCAGAGACCA-3 ], described by Linton et al. [27] ) were used. Strains were considered to be different if they had у1 major band difference from other strains run on the same gel with the same primer, with a minimum of 3 primers used for comparison, as described elsewhere [24] .
Disinfectant Activity of BC against M. abscessus
Suspension method. Isolates of rapidly growing mycobacteria including M. abscessus-type strain ATCC (American Type Culture Collection) 19977 and an isolate from the outbreak of infection were tested for survival in commercial BC (Zephiran; Sanofi Pharmaceuticals) using the Clinical Research Associates suspension method [28] . Commercial BC was tested at the 1:750 dilution against M. abscessus ATCC 19977 and diluted 1:10 (final dilution, 1:7500, or 0.01%) with sterile water and tested against ATCC 19977 and an outbreak isolate. An inoculum consistent with a 0.5 McFarland turbidity standard of the organism to be tested (∼ cfu/mL) was prepared and 7 5.0 ϫ 10 added to the test solutions at a ratio of 1 part organism to 9 parts solution. The undiluted and 1:10 dilution of sterile water (control), along with the undiluted and 1:10 dilution of BC, were mixed with the organism and left at room temperature for 10 min. The suspensions were then diluted 1:10 and 1:100, and 100 mL of each was plated on trypticase soy agar. Plates were incubated at 30ЊC and observed at 7 days for growth.
Disk diffusion testing. A disk diffusion assay was also performed in which 20 mL of undiluted BC or a 1:10 dilution of BC was added to paper disks, which were then placed on a Mueller-Hinton agar plate that had been streaked with the test organism. Zones of growth inhibition after 72 h of incubation at 30ЊC were then recorded. 
RESULTS
Case Finding
Sixty-nine joint or soft-tissue injections were administered to 58 persons from 1 April through 31 July 1999 (figure 1). Fortythree persons (74%) were female, and 15 (26%) were male; the mean age was 64 years. Twelve persons (21%; 9 women and 3 men) who had received intra-articular or periarticular injections during the period of 1 April through 31 July 1999 had contracted postinjection site infections caused by M. abscessus. Case patients did not differ significantly from non-case patients by age or sex. The difference in attack rates between male and female patients was not statistically significant. The demographic characteristics of and diagnostic test results for the 10 patients with culture-confirmed cases of infection and 2 patients with presumptive cases of infection are shown in table 1. The median time from injection date to onset of symptoms was 75 days (range, 24-284 days).
The infection sites included the knee (5 patients [42%]), heel (4 [33%]), and elbow, shoulder, and gluteal region (1 each [25%]) (table 2). The attack rates, by injection site, were as follows: heel, 67% (4 of 6); knee, 31% (5 of 16); shoulder, 8% (1 of 12) ; elbow, 25% (1 of 4); and gluteus, 10% (1 of 10). Surgical intervention or debridement was performed for 8 (67%) of the 12 case patients. Ten case patients recovered completely, and 2 were lost to follow-up. The average duration of medical treatment among the 10 patients who recovered was 24 weeks (range, 8-48 weeks).
Findings for Environmental Samples
We recovered rapidly growing mycobacteria from 4 (14%) of the 28 environmental specimens. Ten specimens (including 9 from preparations with BC) yielded contaminants that prevented isolation of mycobacteria. Rapidly growing mycobacteria were not recovered from the other specimens obtained. The 4 mycobacteria-positive environmental specimens were linked to BC preparations: BC-soaked cotton ball samples taken from examination rooms 1 and 3, a swab sample from the metal container of the soaked cotton balls from room 3, and a sample of diluted BC that was obtained via a sterile syringe from a container of BC-soaked gauze in room 2 (table 3). At least 1 culture-positive sample was obtained from each of the 3 examining rooms.
Organism Identification
The 10 isolates recovered from case patients and the 4 environmental isolates were identified by standard methods as M. abscessus. The species identification of the 14 isolates was confirmed by PCR restriction analysis [21] . Except for 1 case patient isolate, all isolates were further analyzed by PFGE and RAPD-PCR. abscessus [22] . The remaining 6 control strains had intact genomic DNA and produced satisfactory PFGE patterns. Two of the patterns were identical (they were chosen as controls because they had previously been found to be identical by PFGE), whereas the other 4 patterns were unique.
RAPD-PCR Findings
The 9 case patient isolates, 4 environmental isolates, and 12 control strains of M. abscessus yielded satisfactory DNA preparations. The 13 outbreak-related isolates all had RAPD-PCR patterns identical to those of the 4 test primers. Of the 12 control strains, 9 produced unique patterns by RAPD-PCR, PFGE, or both, whereas 3 unrelated isolates produced the same pattern as the outbreak strains with use of the 4 primers. A photomicrograph of the RAPD-PCR products for the 8 case patient isolates is shown in figure 2 .
Disinfectant Activity of BC against M. abscessus
Suspension method. By use of the Clinical Research Associates suspension method [28] , exposure of the M. abscessus-type strain ATCC 19977 to commercial-strength BC (dilution, 1:750) for 10 min failed to kill the organism (the outbreak strain was not tested). At a 1:7500 dilution of BC, the ATCC 19977 strain and the outbreak strain were also not killed. ATCC 19977 showed some reduction in colony counts in 1:750 BC compared with a water dilution control, whereas almost no reduction in colony counts was seen with either the ATCC 19977 strain or the outbreak strain at the 1:7500 dilution. Disk diffusion testing. Disk diffusion testing revealed that full-strength BC (dilution, 1:750) produced disk zone diameters (9-11 mm) of growth inhibition nearly identical to those of the outbreak isolate, M. abscessus-type strain ATCC 19977, and 4 random clinical isolates of M. abscessus. With a 1:10 dilution of the commercial-strength BC, the outbreak strains, like M. abscessus-type strain ATCC 19977 and other control strains of M. abscessus, showed no growth inhibition.
DISCUSSION
We cultured M. abscessus from samples obtained from 10 of 12 case patients who acquired postinjection intra-articular or periarticular infections after intra-articular or periarticular steroid injections were administered by one physician. We also cultured M. abscessus from 4 environmental samples that contained diluted BC used as an antiseptic in the same physician's clinic. RAPD-PCR analysis revealed that the case patient strains and environmental strains of M. abscessus were identical. Laboratory studies confirmed that M. abscessus was relatively resistant to the commercial dilution of BC (1:750, or 0.13%) and that there was no measurable activity when diluted 1:10 (1:7500, or 0.01%). The estimated dilution of the antiseptic used during this outbreak of infection was 1:6000. Although the level of inactivation by the soaked cotton balls was not determined, those recovered from 2 of the 3 examination rooms were culture positive for the outbreak strain of M. abscessus. To our knowledge, this is the first outbreak of postinjection infection in which Mycobacterium species were recovered from BC antiseptic and the second in which rapidly growing mycobacteria were associated with BC use. These rapidly growing mycobacteria are of particular interest as nosocomial pathogens because of their relative resistance to disinfectants, chlorine, and glutaraldehyde [29] [30] [31] . The other outbreak of infection involving mycobacteria and BC occurred at an allergy clinic in Georgia [16] at which diluted BC stored in containers with cotton balls was used for skin disinfection. In that outbreak, the causative organism, M. chelonae, was not recovered from environmental samples. Most reported outbreaks of postinjection abscesses caused by Mycobacterium fortuitum and other members of the M. fortuitum complex [16, 25, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] have been secondary to the use of multidose vials or poorly sterilized needles [33-35, 38, 39, 42] . For this outbreak, we could not assess what role, if any, multidose vials of betamethasone or lidocaine HCl might have played.
From 1955 through 1982, the misuse of BC was associated with numerous other outbreaks or pseudooutbreaks of postinjection infection caused by bacterial species [2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The most common species were aerobic, gram-negative bacilli, including Burkholderia (Pseudomonas) cepacia, Serratia marcescens, and Enterobacter species (table 4).
To our knowledge, this is the first description of BC's lack of activity against a rapidly growing Mycobacterium species, M. abscessus. Our study determined that BC is ineffective against M. abscessus, even when used in accordance with the manufacturer's instructions, and infection with this organism is a definite risk when BC is used. Although certain second-and third-generation quaternary ammonium compounds inhibit the growth of mycobacteria, they are not bactericidal [29, 30] . Thus, BC and other quaternary ammonium compounds are inappropriate antiseptics when mycobacteria are potentially present.
Similar to other quaternary ammonium compounds, the limited disinfecting property of BC is even more diminished in the presence of organic material (e.g., gauze and cotton) [1, 10] . Therefore, BC should never be stored with these products. In this outbreak, BC was diluted to ∼1:6000 and then stored in the presence of organic materials that inactivate the compound.
The exact source of M. abscessus in this outbreak of infection was not determined, because unopened containers of distilled water and the undiluted BC were culture negative. However, like other species of rapidly growing mycobacteria [31, 42] , M. abscessus is a common environmental species, and it has been recovered from tap water. Rapidly growing mycobacteria are also known to grow and survive indefinitely in distilled water [43, 44] , and they have been recovered from opened bottles of distilled water in other outbreaks of postinjection infection [41] . Because all of the examination rooms were contaminated, the organism was probably introduced from contaminated distilled water, cotton, or the container used to dilute the BC.
This investigation had limitations that prevented us from identifying the exact source of contamination. Because the physician had relocated to a new office before our visit, we were unable to obtain specimens from several items that had been used previously. These items included the same batches of distilled water, multidose injection vials of steroids and lidocaine HCl, and cotton balls. The original mixing jug that was used for preparing diluted BC was discarded during the relocation.
We recommend that BC not be used as an antiseptic. Although quaternaries are considered to be low-level disinfectants [29] , the quaternary disinfectant BC continues to be commercially available and to be used by physicians as an antiseptic [17] . In 1975, the Centers for Disease Control and Prevention stated, "Because of the availability of preferable alternative agents, we see very few applications for aqueous quaternary ammonium compounds in hospitals other than for the ordinary environmental sanitation of such non-critical surfaces as walls and furniture" [10, p. 2417] . Forty years after being first reported [2] , outbreaks of disease following the use of BC are still occurring. The pathogen might have changed, but the problem remains the same.
